References

Short communication: understanding the barriers to cervical cancer prevention and HPV vaccination in Saudi Arabia.

10.3390/v16060974 · 2024 · External reference

Eleven-year review of data on Pap smears in Saudi Arabia: we need more focus on glandular abnormalities!

10.5144/0256-4947.2017.265 · 2017 · External reference

Prevalence and predictive factors of cervical cancer screening in Saudi Arabia: a nationwide study.

2023 · External reference

Assessing Saudi women’s awareness about human papillomavirus (HPV) and their susceptibility to receive the vaccine.

10.1080/21645515.2024.2395086 · 2024 · External reference

New frontiers in locally advanced cervical cancer treatment.

10.3390/jcm13154458 · 2024 · External reference

Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer.

10.1186/s12885-024-12358-8 · 2024 · External reference

Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.

10.1186/s12885-022-10406-9 · 2022 · External reference

Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry.

10.1038/s41598-018-20325-0 · 2018 · External reference

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

10.1016/s0140-6736(24)01808-7 · 2024 · External reference

An arm and a leg: the rising cost of cancer drugs and impact on access.

10.1200/edbk_100028 · 2021 · External reference

International cost-effectiveness analysis of chemoradiotherapy plus pembrolizumab for locally advanced cervical cancer.

10.3802/jgo.2025.36.e106 · 2025 · External reference

Cost-effectiveness of pembrolizumab with chemoradiotherapy for locally advanced cervical cancer.

10.1001/jamanetworkopen.2025.0033 · 2025 · External reference

Healthcare transformation in Saudi Arabia: an overview since the launch of vision 2030.

10.1177/11786329221121214 · 2022 · External reference

Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.

10.1186/s12916-021-02204-0 · 2022 · External reference

Cervical cancer.

10.1016/s0140-6736(18)32470-x · 2019 · External reference

Dealing with time in health economic evaluation: methodological issues and recommendations for practice.

10.1007/s40273-015-0309-4 · 2015 · External reference

Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.

10.1056/nejmoa2112435 · 2021 · External reference

Improved curve fits to summary survival data: application to economic evaluation of health technologies.

10.1186/1471-2288-11-139 · 2011 · External reference

Recommendations on the use of structured expert elicitation protocols for healthcare decision making: a good practices report of an ISPOR task force.

10.1016/j.jval.2024.07.027 · 2024 · External reference

Health-related quality of life of patients with cervical cancer according to the duration of treatment and cancer progression.

10.31557/apjcp.2022.23.6.1945 · 2022 · External reference

Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: a United States-based cost-effectiveness analysis.

10.1016/j.ygyno.2022.06.015 · 2022 · External reference

Health state utilities for non small cell lung cancer.

10.1186/1477-7525-6-84 · 2008 · External reference

Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: a systematic review.

10.1371/journal.pone.0266934 · 2022 · External reference

Performance-based risk-sharing arrangements (PBRSA): is it a solution to increase bang for the buck for pharmaceutical reimbursement strategy for our nation and around the world?

10.1007/s40261-020-00972-w · 2020 · External reference

Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia.

10.1016/j.jsps.2020.04.006 · 2020 · External reference

Colorectal cancer-related resource utilization and healthcare costs in Saudi Arabia.

10.1016/j.jsps.2023.101822 · 2023 · External reference